A5008794849- Oxidative Organic Chemistry Reactions
- Vanadium and Halogenation Chemistry
- CAR-T cell therapy research
- Asymmetric Synthesis and Catalysis
- Chemical Synthesis and Reactions
- Chemical Synthesis and Analysis
- Asymmetric Hydrogenation and Catalysis
- Alkaloids: synthesis and pharmacology
- Cancer Research and Treatments
- Protein Degradation and Inhibitors
- Immunotherapy and Immune Responses
- Polyomavirus and related diseases
- Hematopoietic Stem Cell Transplantation
- Axial and Atropisomeric Chirality Synthesis
- Cancer Immunotherapy and Biomarkers
- Sarcoma Diagnosis and Treatment
- Immune Cell Function and Interaction
- Multicomponent Synthesis of Heterocycles
- Cutaneous Melanoma Detection and Management
- Molecular spectroscopy and chirality
- Melanoma and MAPK Pathways
Sun Yat-sen University
2013-2024
Sun Yat-sen University Cancer Center
2013-2024
Innovation Team (China)
2024
Ankang University
2024
11548 Background: TAEST16001 cells are genetically engineered autologous T expressing high-affinity NY-ESO-1-specific T-cell receptor (TCR) targeting NY-ESO-1 (expressed in a wide range of tumors) positive soft tissue sarcoma (STS) the context HLA-A*02:01. A phase I study patients with advanced STS (NCT04318964) demonstrated safety and preliminary indication efficacy at ASCO 2022. Here, we will present our encouraging IIa results. Methods: This is an open-labeled, single arm to evaluate...
11502 Background: NY-ESO-1 is a cancer/testis antigen with expression in wide range of tumor types. TAEST16001 cells are genetically engineered autologous T that express high-affinity NY-ESO-1-specific T-cell receptor (TCR) targeting NY-ESO-1+ soft tissue sarcoma the context HLA-A*02:01. Here, we report preliminary results from an ongoing, dose-escalation and expansion study HLA-A*02:01 positive patients advanced expressing antigen. Methods: This open, single arm, to evaluate safety,...
To identify the causes and corresponding management of adverse reactions during treatment malignant tumors using cytokine-induced killer cells.From January 2012 to December 2012, 441 patients received a total 1,393 autologous cell transfusion cycles in our department. The after procedures were observed (assessed National Cancer Institute Common Toxicity version 2.0), targeted care health education delivered by nurses.All sessions successfully completed, following found: grade 1/3 fever 1.36%...